Core Points - The United States is increasing the domestic manufacturing of amoxicillin to address a national shortage, with Walmart and McKesson partnering with USAntibiotics to ensure supply [1][2] - USAntibiotics aims to meet 100% of the nation's demand for amoxicillin, which is crucial for treating bacterial infections, especially in children [2][6] - Walmart's commitment includes investing an additional $350 billion in U.S.-sourced products by 2030, reinforcing its support for domestic manufacturing [8][9] Company and Industry Insights - The partnership between Walmart, McKesson, and USAntibiotics is seen as a significant step towards enhancing U.S. health security and reducing reliance on foreign pharmaceutical supply chains [2][5] - The FDA declared a national shortage of amoxicillin in 2022, highlighting vulnerabilities in the U.S. supply chain that depend on imports from countries like China and India [8] - The move aligns with broader industry trends advocating for onshoring pharmaceutical manufacturing to improve supply chain resilience and reduce drug costs for consumers [5][10][12]